menu
    • menu
    [{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PLX cells","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"PLX-R18","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic PLX-PAD Cell","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"European Union\u2019s Horizon Europe","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"PLX-PAD","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Pluri","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"","sponsorNew":"Pluri \/ European Union\u2019s Horizon Europe","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ European Union\u2019s Horizon Europe"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"PLX-R18","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pluri \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Pluri","sponsor":"Bar-Ilan University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Emiplacel","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Bar-Ilan University","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Bar-Ilan University"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cell-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Avoplacel","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Pluri","sponsor":"Bar-Ilan University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"MAIT Cell-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pluri \/ Bar-Ilan University","highestDevelopmentStatusID":"14","companyTruncated":"Pluri \/ Bar-Ilan University"}]

    Find Clinical Drug Pipeline Developments & Deals by Pluri

    Menu

    Pluri

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MAIT Cell-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Bar-Ilan University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pluri And Bar-Ilan University Advance Solid Tumor Cancer Immunotherapy

                            Details : The collaboration aims to support the continued development of Placental Mucosal Associated Invariant T cells for solid tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : MAIT Cell-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Bar-Ilan University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avoplacel

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $4.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NIH Exercises Option to Fund $1.4 Million for Pluri’s Acute Radiation Syndrome Contract

                            Details : The company will manufacture the PLX-R18 cell therapy and conduct in vitro and in vivo studies to develop it as a potential treatment for hematopoietic complications of the acute radiation syndrome.

                            Brand Name : PLX-R18

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 06, 2024

                            Lead Product(s) : Avoplacel

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $4.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cell-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pluri Launches Immunotherapy Platform for Solid Tumour Cancer Treatment

                            Details : Pluri's MAIT (placental allogeneic MAIT platform) will use cells isolated from the human placenta, a source rich in highly potent allogeneic immune cells, which will be used for solid tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 04, 2024

                            Lead Product(s) : Cell-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

                            Details : The company has launched its placental allogeneic MAIT cell platform to identify ideal target antigens for CAR therapy, potentially enhancing tumor infiltration and efficacy in solid tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 02, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emiplacel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Bar-Ilan University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

                            Details : Through the agreement, Pluri will focus on the development of PLX-PAD cells (emiplacel), that exhibit immune-modulating capabilities, for the treatment of patients with cocaine addictions.

                            Brand Name : PLX-PAD

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 05, 2024

                            Lead Product(s) : Emiplacel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Bar-Ilan University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLX-R18

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $4.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluris PLX-R18 in C...

                            Details : The net funding will be used to advance the development of its PLX-R18 cell therapy as a potential novel treatment for Hematopoietic Acute Radiation Syndrome (H-ARS).

                            Brand Name : PLX-R18

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 11, 2023

                            Lead Product(s) : PLX-R18

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $4.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLX-PAD

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : European Union’s Horizon Europe

                            Deal Size : $7.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            €7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri’s PLX-PAD Cells for Ost...

                            Details : The goal of the PROTO project is to utilize Pluri’s PLX-PAD cells in a Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis (OA).

                            Brand Name : PLX-PAD

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 06, 2022

                            Lead Product(s) : PLX-PAD

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : European Union’s Horizon Europe

                            Deal Size : $7.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic PLX-PAD Cell

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surge...

                            Details : Patients treated with PLX-PAD (allogeneic PLX-PAD Cell) showed an increase of 2.3kg from reference (week 6) to week 26 compared to 0.51kg in the placebo group, a 1.8kg difference (p=0.073).

                            Brand Name : PLX-PAD

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 13, 2022

                            Lead Product(s) : Allogeneic PLX-PAD Cell

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLX-R18

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reducti...

                            Details : Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients. PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a fav...

                            Brand Name : PLX-R18

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 23, 2022

                            Lead Product(s) : PLX-R18

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pluri

                            Israel arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLX-PAD

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fract...

                            Details : PLX-PAD cells demonstrated statistically significant superiority, in ability to increase muscle strength and volume for patients who have undergone total hip replacement surgery due to osteoarthritis.

                            Brand Name : PLX-PAD

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 15, 2021

                            Lead Product(s) : PLX-PAD

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth